Inform, Empower, Connect

Part of the Myrovlytis Trust
Contact Us



Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors

Last Update Posted : 2013-06-05

The aim of the trial

  • This phase I trial is studying the side effects and best dose of erlotinib when given with temozolomide in treating young patients with recurrent or refractory solid tumors. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving erlotinib with temozolomide may kill more tumor cells.
Country
United States,
Locations
Arcadia,
Trial Type
Interventional
Trial Phase
Phase 1,
Trial Status
Completed
Minimum age
-
Maximum age
21 Years
Key Contact
----
Clinical Trial ID
NCT00077454
URL
https://clinicaltrials.gov/ct2/show/record/NCT00077454

Key Information

  • -

How the treatment works

  • Given orally (PO)
  • Visit our drugs and interventions page to find out more about this treatment, including how it works and what it’s used for.

Who is the trial for?

  • One of the following histologically confirmed solid tumors:
  • Brain tumors
  • Osteogenic sarcoma
  • Rhabdomyosarcoma
  • Soft tissue sarcoma (excluding Ewing's sarcoma)
  • Neuroblastoma
  • Germ cell tumors
  • Recurrent or refractory disease
  • No known curative therapy exists
  • Performance status - Karnofsky 50-100% (for patients age 11 to 21)
  • Performance status - Lansky 50-100% (for patients age 10 and under)
  • At least 8 weeks
  • Absolute neutrophil count > 1,000/mm^3
  • Platelet count > 100,000/mm^3 (transfusion independent*)
  • Hemoglobin > 8.0 g/dL (transfusion allowed)
  • Bilirubin < 1.5 times upper limit of normal (ULN)
  • ALT < 2.5 times ULN
  • Albumin ≥ 2 g/dL
  • Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min
  • Creatinine based on age as follows:
  • ≤ 0.8 mg/dL for patients age 5 and under
  • ≤ 1.0 mg/dL for patients 6 to 10
  • ≤ 1.2 mg/dL for patients 11 to 15
  • ≤ 1.5 mg/dL for patients age 15 to 21
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Able to swallow tablets (for patients in part 2 only)
  • No uncontrolled infection
  • Recovered from all prior immunotherapy
  • At least 7 days since prior biologic therapy
  • At least 3 months since prior stem cell transplantation and no evidence of active graft-versus-host disease
  • More than 1 week since prior growth factors
  • No concurrent prophylactic growth factor therapy
  • No concurrent immunotherapy
  • No concurrent biologic therapy
  • More than 2 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas) and recovered
  • No other concurrent chemotherapy
  • No concurrent systemic corticosteroids except for treatment of increased intracranial pressure or symptomatic tumor edema in patients with CNS tumors
  • No concurrent steroids as an antiemetic
  • Concurrent dexamethasone for patients with CNS tumors allowed provided patient has been on a stable or decreasing dose for at least 1 week before study entry
  • Recovered from all prior radiotherapy
  • At least 2 weeks since prior local palliative radiotherapy (small port)
  • At least 6 weeks since prior substantial bone marrow irradiation
  • At least 6 months since prior craniospinal radiotherapy
  • At least 6 months since prior radiotherapy to 50% or more of the pelvis
  • At least 8 weeks since prior standard-fraction radiotherapy for patients with recurrent brain tumors unless there is biopsy proof of recurrent tumor
  • Prior radiosurgery within the past 9 months allowed provided there is documentation of progressive disease by biopsy, positron-emission tomography (PET) scan, or MR spectroscopy
  • No concurrent radiotherapy
  • More than 1 week since prior CYP3A4 inhibitors
  • More than 4 weeks since prior CYP3A4 inducers
  • More than 5 days since prior proton-pump inhibitors
  • More than 2 days since prior H_2 blockers
  • No prior erlotinib
  • No concurrent enzyme-inducing anticonvulsants
  • No concurrent proton-pump inhibitors
  • No concurrent H2 blockers
  • No other concurrent investigational agents
  • Concurrent antacids allowed provided the antacid is not administered 2 hours before, during, and 2 hours after erlo

Disclaimer

  • ONTEX is intended to supplement, not replace, your healthcare team. Patients should always discuss a clinical trial with their healthcare team. If a patient is eligible for a trial the trial team will be able to provide more in-depth information about the trial so the patient can make an informed decision before taking part. Trial information has been sourced from www.clinicaltrials.gov. The content is then reviewed weekly by the Osteosarcoma Now team. All the trials also have a patient-friendly summary and key information section written by the team at Osteosarcoma Now. We have also included a description of the medications being used in the trial and summarised the inclusion and exclusion criteria in the ‘who is this trial (not) for’ sections. To the best of our knowledge the clinical trial database is up-to-date and accurate.However, we cannot assume any liability for the accuracy or completeness of the information.
Back to Results Page